IDORSIA LTD |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.95 CHF | +7.14% |
|
+4.84% | -7.76% |
| Apr. 11 | Swiss Market Index Falls as ECB Signals June Rate Cut | MT |
| Apr. 11 | Idorsia to Revise July 2024 Convertible Bond Terms, Conditions | MT |
| Sales 2023 * | 126M 138M | Sales 2024 * | 272M 298M | Capitalization | 349M 382M |
|---|---|---|---|---|---|
| Net income 2023 * | -407M -446M | Net income 2024 * | -401M -439M | EV / Sales 2023 * | 11.3 x |
| Net Debt 2023 * | 1.08B 1.19B | Net Debt 2024 * | 1.12B 1.23B | EV / Sales 2024 * | 5.41 x |
| P/E ratio 2023 * |
-0.88
x | P/E ratio 2024 * |
-1.28
x | Employees | 650 |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 58.73% |
More Fundamentals
* Assessed data
More news
Latest transcript on Idorsia Ltd
More recommendations
More press releases
More news
| 1 day | +7.14% | ||
| 1 week | -22.80% | ||
| Current month | -31.05% | ||
| 1 month | +6.97% | ||
| 3 months | +28.71% | ||
| 6 months | -2.69% | ||
| Current year | -7.76% |
1 week
1.65
2.16
1 month
1.652.97
Current year
1.293.70
1 year
1.299.94
3 years
1.2927.08
5 years
1.2933.88
10 years
1.2933.88
| Managers | Title | Age | Since |
|---|---|---|---|
Jean-Paul Clozel
CEO | Chief Executive Officer | 69 | 17-05-31 |
André Muller
DFI | Director of Finance/CFO | 60 | 17-05-31 |
Martine Clozel
CTO | Chief Tech/Sci/R&D Officer | 68 | 17-05-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jörn Aldag
BRD | Director/Board Member | 65 | 20-05-12 |
Peter Kellogg
BRD | Director/Board Member | 67 | 21-05-11 |
Jean-Paul Clozel
CEO | Chief Executive Officer | 69 | 17-05-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 773 M€ | -.--% | - | |
| 0.00% | 10 M€ | -3.35% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-18 | 1.95 | +7.14% | 890,742 |
| 24-04-17 | 1.82 | -15.35% | 1,852,728 |
| 24-04-16 | 2.15 | +3.37% | 710,463 |
| 24-04-15 | 2.08 | +1.36% | 549,822 |
| 24-04-12 | 2.052 | +10.32% | 924,900 |
Delayed Quote Swiss Exchange, April 18, 2024 at 11:30 am EDT
More quotes
Idorsia Ltd is a Switzerland-based biopharmaceutical company, which specializes in the discovery and development of small molecules, to meet significant unmet medical needs. The Company will have a diverse clinical development pipeline comprising several compounds being investigated in multiple therapeutic areas, including central nervous system disorders, cardiovascular disorders, immunological disorders and orphan diseases. The Company's development compounds target a number of different diseases such as: Resistant Hypertension, Systemic lupus erythematosus, Chronic insomnia and Fabry disease, among others.
Calendar
2024-04-25
- Q4 2023 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
A-
Sell
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
8
Last Close Price
1.95
CHF
Average target price
1.724
CHF
Spread / Average Target
-11.60%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -7.76% | 357M | |
| -3.30% | 102B | |
| +1.79% | 96.84B | |
| -0.44% | 21.48B | |
| -18.35% | 20.82B | |
| -7.45% | 18.6B | |
| -40.31% | 16.81B | |
| -26.84% | 13.78B | |
| +0.59% | 13.4B | |
| +20.86% | 11.06B |
- Stock Market
- Equities
- IDIA Stock
